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Neuropeptide Y (NPY) is abundant in the nervous system.
It acts through Y1, Y2, Y4 and Y5 receptors and is involved
in a variety of brain functions. When applied locally into
the amygdala, NPY exerts an anxiolytic action, presuma-
bly mediated by Y1 receptors. Depletion of Y2 receptors
induces an anxiolytic phenotype, possibly by abolishing
the release-inhibiting action of presynaptic Y2 receptors.
In the present study we aimed to find the exact site of the
presumed anxiogenic action mediated by Y2 receptors. We
conducted site-specific deletions of Y2 receptors in Y2lox/lox
mice by local injection of an AAV-Cre vector into the hip-
pocampus and the amygdala. As controls, an AAV-GFP
vector was injected in Y2lox/lox littermates at the same sites.
Expression of Cre and GFP was verified by in situ hybrid-
ization and immunohistochemistry. Deletion of Y2 recep-
tors was visualized by receptor autoradiography and in
situ hybridization. After bilateral injection of an AAV-Cre
vector into the basolateral amygdala, mice revealed a ten-
dency towards an anxiolytic phenotype in the light-dark
test (LDT). When deletion of Y2 receptors was confined to
the central nucleus of the amygdala, an anxiolytic pheno-
type was observed in the elevated plus maze and the LDT.
Moreover, a better stress coping ability was demonstrated
in the tail suspension test. In contrast, no anxiolytic effect
was detected after intrahippocampal injections. The
experiments indicate that the anxiolytic and antidepres-
sant-like effects of Y2 receptor deletion may be generated
in certain subnuclei of the amygdala.
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